Loading organizations...
Biophysical Therapeutics is a Wilmington, Delaware-based biotechnology company that utilizes computational biology to design novel therapeutics targeting cancer, neurodegenerative conditions like Alzheimer's disease, and the biological aging process. The enterprise holds granted patents for both preclinical and repurposed clinical-stage pharmaceutical compounds, including a specific drug designed to reduce metabolic rates to potentially slow aging that is currently undergoing testing in human tissue models. To support its research and development pipeline, the firm has raised $140,000 in total early-stage funding to date, which includes a recent $40,000 convertible note financing round. The company is backed by deep-tech syndicate Reinforced Ventures and maintains a scientific advisory board featuring prominent academics such as Professor George Church, Professor Bruno Conti, and Professor Varinder Aggarwal. Biophysical Therapeutics was officially founded in 2022 by Cambridge biochemistry graduate Dr. Michael Forrest.
Biophysical Therapeutics has raised $190K across 1 funding round.
Biophysical Therapeutics has raised $190K in total across 1 funding round.
Biophysical Therapeutics has raised $190K across 1 funding round. Most recently, it raised $190K Seed in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2023 | $190K Seed | — | CrunchFund, DecentraNet, Fmfw.io, Galaxy Digital, Monday Capital, Republic Capital, Scout Ventures, Symbolic Capital, Wave Financial, Adam Back, Brad Yasar, Craig Sellars, George Burke | Announced |
Biophysical Therapeutics has raised $190K in total across 1 funding round.
Biophysical Therapeutics's investors include CrunchFund, DecentraNet, FMFW.io, Galaxy Digital, Monday Capital, Republic Capital, Scout Ventures, Symbolic Capital, Wave Financial, Adam Back, Brad Yasar, Craig Sellars.
Biophysical Therapeutics is a biotech startup developing drugs targeting cancer, age-related diseases like Alzheimer's, and aging itself through a computational biology platform.[1][2][4] The company designs and discovers novel, experimentally-validated drugs, serving pharmaceutical researchers and patients in oncology and geriatrics, addressing unmet needs in disease treatment and longevity.[2][3][4] Valued at $6.5 million in 2023, it has pursued crowdfunding via platforms like Wefunder, indicating early-stage growth momentum in the competitive biotech space.[2]
Biophysical Therapeutics Ltd was incorporated in the UK in 2017, as recorded in official Companies House filings, marking its formal launch as a biotech entity.[5] While specific founders are not detailed in available records, the company emerged from advancements in computational biology, focusing on drug discovery for complex diseases.[2] Early traction includes building a pipeline of validated drugs and a 2023 Wefunder campaign, highlighting its pivot toward accessible funding to accelerate development amid rising interest in aging research.[2]
Biophysical Therapeutics rides the wave of AI-driven drug discovery and the exploding longevity biotech sector, where computational tools accelerate R&D amid aging global populations.[1][2] Timing aligns with surging investments in anti-aging—market forces like FDA interest in senescence-targeted therapies and breakthroughs in protein modeling (e.g., AlphaFold) favor platforms like theirs.[3][4] It contributes to the ecosystem by validating computational approaches for "moonshot" goals like reversing aging, potentially influencing pharma partnerships and reducing development timelines from years to months.
Biophysical Therapeutics is poised for milestone advancements, such as preclinical trial data or Series A funding, fueled by its validated pipeline and crowdfunding base.[2] Trends like AI-biotech convergence and personalized medicine will shape its path, amplifying impact if it secures big-pharma collaborations. Its influence could grow by pioneering aging-as-a-disease treatments, transforming it from startup to longevity leader—echoing its core mission to combat cancer and aging head-on.[4]
